Literature DB >> 17059470

Protective role of protein C inhibitor in monocrotaline-induced pulmonary hypertension.

Y Nishii1, E C Gabazza, H Fujimoto, H Nakahara, T Takagi, N Bruno, C N D'Alessandro-Gabazza, J Maruyama, K Maruyama, T Hayashi, Y Adachi, K Suzuki, O Taguchi.   

Abstract

BACKGROUND: Protein C inhibitor (PCI) plays a role in multiple biological processes including fertilization, coagulation, fibrinolysis and kinin systems.
OBJECTIVES: We hypothesized that PCI participates in the pathogenesis of pulmonary hypertension. To demonstrate this, we compared the development of pulmonary hypertension in mice overexpressing PCI in the lung with wild-type (WT) mice. Pulmonary hypertension was induced by s.c. injection of 600 mg kg-1 of monocrotaline weekly for 8 weeks.
RESULTS: Right ventricular arterial pressure was significantly increased in monocrotaline-treated WT mice compared with that in monocrotaline-treated transgenic mice. Bronchoalveolar lavage fluid (BALF) levels of thrombin-antithrombin complex, monocyte chemoattractant protein-1 and platelet-derived growth factor, and the plasma level of tumor necrosis factor-alpha were significantly increased in monocrotaline-treated WT mice as compared with monocrotaline-treated PCI transgenic mice. Increased level of PCI-thrombin complex was detected in BALF from monocrotaline-treated PCI transgenic mice as compared with saline-treated PCI transgenic mice.
CONCLUSIONS: This study showed that increased expression of PCI in the lung is protective against monocrotaline-induced pulmonary hypertension, suggesting a potential beneficial effect of PCI for the therapy of this disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17059470     DOI: 10.1111/j.1538-7836.2006.02174.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  11 in total

1.  Expression patterns of protein C inhibitor in mouse development.

Authors:  Gerry T M Wagenaar; Pavel Uhrin; Klara Weipoltshammer; Marlene Almeder; Pieter S Hiemstra; Margarethe Geiger; Joost C M Meijers; Christian Schöfer
Journal:  J Mol Histol       Date:  2010-03-14       Impact factor: 2.611

2.  Effect of thrombomodulin on the development of monocrotaline-induced pulmonary hypertension.

Authors:  Yasuharu Yamada; Junko Maruyama; Erquan Zhang; Amphone Okada; Ayumu Yokochi; Hirofumi Sawada; Yoshihide Mitani; Tatsuya Hayashi; Koji Suzuki; Kazuo Maruyama
Journal:  J Anesth       Date:  2013-07-02       Impact factor: 2.078

Review 3.  The Serpin Superfamily and Their Role in the Regulation and Dysfunction of Serine Protease Activity in COPD and Other Chronic Lung Diseases.

Authors:  Gillian A Kelly-Robinson; James A Reihill; Fionnuala T Lundy; Lorcan P McGarvey; John C Lockhart; Gary J Litherland; Keith D Thornbury; S Lorraine Martin
Journal:  Int J Mol Sci       Date:  2021-06-14       Impact factor: 5.923

4.  Is protein C inhibitor antithrombotic and protective in pulmonary hypertension?

Authors:  L M Beaulieu; F C Church
Journal:  J Thromb Haemost       Date:  2006-09-15       Impact factor: 16.036

5.  Pulmonary oxidative stress is increased in cyclooxygenase-2 knockdown mice with mild pulmonary hypertension induced by monocrotaline.

Authors:  Francesca Seta; Mahboubeh Rahmani; Patricia V Turner; Colin D Funk
Journal:  PLoS One       Date:  2011-08-05       Impact factor: 3.240

6.  Effects of Single Drug and Combined Short-term Administration of Sildenafil, Pimobendan, and Nicorandil on Right Ventricular Function in Rats With Monocrotaline-induced Pulmonary Hypertension.

Authors:  Telma M Nakata; Ryou Tanaka; Rieko Yoshiyuki; Toshiharu Fukayama; Seijiro Goya; Ryuji Fukushima
Journal:  J Cardiovasc Pharmacol       Date:  2015-06       Impact factor: 3.105

Review 7.  Serpins in thrombosis, hemostasis and fibrinolysis.

Authors:  J C Rau; L M Beaulieu; J A Huntington; F C Church
Journal:  J Thromb Haemost       Date:  2007-07       Impact factor: 5.824

8.  Diaphragm atrophy and contractile dysfunction in a murine model of pulmonary hypertension.

Authors:  Bumsoo Ahn; Hyacinth M Empinado; Monsour Al-Rajhi; Andrew R Judge; Leonardo F Ferreira
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

9.  Angiotensin-(1-9) ameliorates pulmonary arterial hypertension via angiotensin type II receptor.

Authors:  Seung Ah Cha; Byung Mun Park; Suhn Hee Kim
Journal:  Korean J Physiol Pharmacol       Date:  2018-06-25       Impact factor: 2.016

Review 10.  Intracellular and extracellular serpins modulate lung disease.

Authors:  D J Askew; G A Silverman
Journal:  J Perinatol       Date:  2008-12       Impact factor: 2.521

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.